Chemotherapy as an Adjuvant to Surgery for Colorectal Cancer

Lawrence, Walter; Terz, José J.; Horsley, J. Shelton; Brown, Peter W.; Romero, C.

doi:10.1001/archsurg.1978.01370140054011

Cited by 42 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These strategies are multidirectional and composed of surgery, radiation therapy, chemotherapy, and targeted therapy (Damin & Lazzaron, 2014). Among them, chemotherapy utilizes different drugs or combinations of them and is administrated as an adjuvant after surgery (Goyle & Maraveyas, 2005;Lawrence et al 1978). Almost half of the CRC patients might develop recurrence due to surgical resection and aggressive chemotherapy, which underscore the necessity of improving novel therapies (de la González-Vallinas et al, 2013;Rangwala et al, 2012; P. R. Subbarayan et al, 2010;Wehler et al, 2013).…”

Section: Inhibition Of the Pi3k/akt/mtor Pathway In Crc Either As Mon...mentioning

confidence: 99%

The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non‐coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles

Sanaei

Khorasani

Pourbagheri‐Sigaroodi

et al. 2021

Journal Cellular Physiology

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the deadliest human malignancies worldwide. Several molecular pathways have been demonstrated to be involved in the initiation and development of CRC which among them, the overactivation of the phosphatidyl‐inositol 3‐kinase (PI3K)/Akt/mTOR axis is of importance. The current review aims to unravel the mechanisms by which the PI3K/Akt/mTOR pathway affects CRC progression; and also, to summarize the original data obtained from international research laboratories on the oncogenic alterations and polymorphisms affecting this pathway in CRC. Besides, we provide a special focus on the regulatory role of noncoding RNAs targeting the PI3K/Akt/mTOR pathway in this malignancy. Questions on how this axis is involved in the inhibition of apoptosis, in the induction of drug resistance, and the angiogenesis, epithelial to mesenchymal transition, and metastasis are also responded. We also discussed the PI3K/Akt pathway‐associated prognostic and predictive biomarkers in CRC. In addition, we provide a general overview of PI3K/Akt/mTOR pathway inhibition whether by chemical‐based drugs or by natural‐based medications in the context of CRC, either as monotherapy or in combination with other therapeutic agents; however, those treatments might have life‐threatening side effects and toxicities. To the best of our knowledge, the current review is one of the first ones highlighting the emerging roles of nanotechnology to overcome challenges related to CRC therapy in the hope that providing a promising platform for the treatment of CRC.

show abstract

Section: Inhibition Of the Pi3k/akt/mtor Pathway In Crc Either As Mon...mentioning

confidence: 99%

The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non‐coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles

Sanaei

Khorasani

Pourbagheri‐Sigaroodi

et al. 2021

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Li and Ross [2] reported an improvement in the cure rate of stage II and III colon cancer with postoperative 5-fluorouracil (5-FU) and set the stage for further studies with the fluorinated pyrimidines (5-FU and fluorodeoxyuridine). In one of the earliest randomized trials in the adjuvant setting, 203 patients were randomized after curative resection to receive intraluminal followed by intravenous 5-FU or no chemotherapy [3]. This study did not reveal any disease-free (DFS) or overall survival (OS) advantage for adjuvant therapy.…”

Section: Clinical Trials Of Adjuvant Chemotherapymentioning

confidence: 99%

Adjuvant chemotherapy for colon cancer

Kumar

Goldberg

2001

Curr Oncol Rep

View full text Add to dashboard Cite

Colon cancer remains the third most common cancer, and cause of cancer-related death in the United States. Greater public awareness and acceptance of screening programs have contributed significantly to increasingly earlier detection of colon cancer and decreased mortality. Advances made in the understanding of this disease, both in terms of its clinical behavior and molecular pathogenesis, have translated into major improvements in its therapy. Several large randomized trials during the last two decades have helped the oncology community forge a successful multi-modality treatment strategy against colon cancer. These studies have defined the role of adjuvant therapy for colon cancer after curative surgery. Despite all the advances, a large number of patients continue to succumb to this disease, and the search for better therapies is still necessary. In this article, we discuss the evolution and the current state of adjuvant chemotherapy in colon cancer and briefly review new developments.

show abstract

“…Once again, there was no significant difference. A cooperative trial involving more than 200 patients, organized by Lawrence to test the concept of Grossi that intralumenal 5-FU administered at the time of surgery would enhance survival, found no advantage for 5-FU over a saline control similiarly administered [39].…”

Section: Adjuvant Trials: Colon Cancermentioning

confidence: 99%

Adjuvant treatment in colorectal cancer: An update

Douglass

1987

World j. surg.

View full text Add to dashboard Cite

Analysisof current and recently completed trials of adjuvant therapy for colorectal cancer permit a few very broad generalizations. Survival of patients initially treated by resection has improved during the past 2 decades, unrelated to adjuvant therapy. While pilot, uncontrolled, and historically controlled studies often suggest a treatment benefit, controlled trials have, to date, failed to show any advantage for adjuvant therapy in colon cancer. For rectal cancer, only those trials including radiation therapy alone or in combination with chemotherapy have provided enhanced patient survival. Superiority of preoperative versus postoperative radiotherapy has not been demonstrated. Of interest is the current United States intergroup trial in colon cancer which is evaluating ievamisole in combination with 5-fluorouracil, based on preliminary experience in a smaller study of the North Central Cancer Treatment Group which suggests that levamisole and 5-fluorouracil may be a potentially beneficial adjuvant combination. Recent reports of pharmacologic modulation of 5-fluorouracil resulting in significantly enhanced response rates in advanced metastatic colorectal cancer invite a trial of this pharmacologic concept for surgical adjuvant therapy.

show abstract

Chemotherapy as an Adjuvant to Surgery for Colorectal Cancer

Cited by 42 publications

References 9 publications

The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non‐coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles

The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non‐coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles

Adjuvant chemotherapy for colon cancer

Adjuvant treatment in colorectal cancer: An update

Contact Info

Product

Resources

About